Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)

BACKGROUND: Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Tislelizumab, an anti-PD1 humanized IgG4 monoclonal antibody, has been demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyang, Zhang, Xiao, Zhang, Jie, Gao, Jiale, Bai, Zhigang, Deng, Wei, Chen, Guangyong, An, Yongbo, Liu, Yishan, Wei, Qi, Han, Jiagang, Li, Ang, Liu, Gang, Sun, Yi, Kong, Dalu, Yao, Hongwei, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044580/
https://www.ncbi.nlm.nih.gov/pubmed/35477432
http://dx.doi.org/10.1186/s12885-022-09554-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044580/
https://www.ncbi.nlm.nih.gov/pubmed/35477432
http://dx.doi.org/10.1186/s12885-022-09554-9

Ejemplares similares